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Abstract
Introduction: Past trials of buprenorphine (BUP) in the treatment of major depressive disorder (MDD) have
displayed favorable results, although its clinical utility was limited by the risk of abuse or physical
dependence. By combining BUP with samidorphan (SAM), the euphoric high is negated by an opposing
mechanism, which theoretically reduces addictive-like properties while allowing the antidepressant
properties to remain. As such, the objective of this article is to analyze the results of BUP/SAM
premarketing clinical trials as adjunctive treatment for treatment-resistant MDD.
Methods: A comprehensive PubMed/MEDLINE search was conducted through November 9, 2017, using the
following search terms: depression, samidorphan, buprenorphine, ALKS-5461. Additional data were obtained
from Clinicaltrials.gov and resources included in the present study. All English-language clinical trials
evaluating the combination of BUP/SAM in the treatment of MDD were included.
Results: A few premarketing studies have evaluated the efficacy and safety of BUP/SAM combination as
adjunctive treatment in patients with treatment-resistant MDD. The FORWARD-1 through FORWARD-5 trials
concluded (1) the most effective dosing ratio of BUP/SAM to reduce abuse potential was 1:1; (2) statistically
significant changes in scores from baseline on the Montgomery-Asberg Depression Rating Scale were noted
for the 2 mg/2 mg dose compared with placebo; and (3) the most commonly reported adverse effects were
nausea, dizziness, and fatigue.
Discussion: Buprenorphine/samidorphan has shown favorable results for efficacy and tolerability in
premarketing studies evaluating its use as adjunctive therapy for treatment-resistant MDD. Its novel
mechanism targeting the opioid pathway may serve as a promising antidepressant devoid of abuse
potential.
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Background
In 2015, approximately 6.7% of adults in the United States
experienced a major depressive episode, which translates
to an estimated 16.1 million individuals.1 Despite numer-
ous therapeutic options, only about one third of patients
will achieve remission after the first medication trial.2 In
addition, after each subsequent medication trial, the
likelihood of achieving remission further declines.3 These
individuals who fail multiple antidepressant therapies may
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be classified as ‘‘treatment resistant.’’ It is estimated that
roughly half of all patients treated with antidepressants
will likely experience a chronic, recurrent course of major
depressive disorder (MDD), thus emphasizing the need for
alternative treatments.4 However, most first- and second-
line agents are mechanistically similar in that their
primary function is to modulate the neuronal transmission
of monoamines by increasing synaptic levels of serotonin,
norepinephrine, and/or dopamine (DA).5 Even the rela-
tively new antidepressants, such as vortioxetine, vilazo-
done, and levomilnacipran, have a large degree of
monoamine-targeted mechanistic overlap already seen
with classic antidepressants, such as selective serotonin
reuptake inhibitors (SSRIs) and serotonin norepinephrine
reuptake inhibitors (SNRIs).6 This singular focus on this
pharmacologic strategy has resulted in a paucity of novel
antidepressants targeting subgroups of resistant depres-
sion, such as those of different underlying pathophysiol-
ogy.
As such, a different etiologic hypothesis of MDD involves
the opioid pathway. Prior to the development of mono-
amine oxidase inhibitor antidepressants in the 1950s,
opioids were considered a therapeutic approach in the
treatment of MDD.7 The endogenous peptides dynorphins
(DYNs), enkephalins, endorphins, and endomorphins bind
to the 3 main opioid receptors mu, delta, and kappa in the
central nervous system.8 Endomorphins and endorphins
have a high affinity for the mu opioid receptor (MOR),
whereas enkephalins and DYNs have a much lower
affinity.8 Mu opioid receptor activation is responsible for
the analgesic effects of opioids, although this also drives
unwanted side effects, such as acute euphoria, respiratory
depression, or physical dependence after prolonged
exposure.8 Dynorphins display high affinity for the kappa
opioid receptor (KOR) and were initially investigated to
elicit analgesia similarly to MOR but with less incidence of
euphoria and reinforcement.9,10 Incidentally, KOR agonism
contributed to the mood-related side effect of dysphoria.
This discovery sparked exploration into antidepressant-like
effects via KOR antagonism.10
Kappa opioid receptors located within the mesolimbic
region of the brain are essential for regulating mood and
affective disorders.11 GABAergic neurons projecting from
the nucleus accumbens release DYN, which binds and
activates KORs located on ventral tegmental area
dopaminergic neurons to inhibit dopaminergic firing.12
This decrease in DA transmission has been associated
with dysphoria and anhedonia-related symptoms, as well
as the modulation of mood and stress.13 Pro-DYN
knockdown mice exhibited a reduction in depressive-like
behavior, implicating a potential role for KOR antagonists
in the treatment of MDD to prevent DYN-mediated DA
depletion.14 The relationship between DYN, KOR, and DA
is shown in the Figure, part A.
The role of KOR antagonism in depression has been
largely explored in rodent and other animal models,
primarily by using the forced swim test. The forced swim
test is a behavioral test based on the learned helplessness
model of depression, which can be used to evaluate the
FIGURE: Mechanism of action of buprenorphine/samidorphan (BUP/SAM) (A) In the absence of kappa opioid receptor
(KOR) antagonism, endogenous dynorphin (DYN) activates KOR-mediated dopaminergic inhibition, which may lead to
depressive-like symptoms of dysphoria and anhedonia. (B) In the presence of KOR antagonism via BUP/SAM, KOR-
mediated dopaminergic inhibition is blocked, facilitating increased dopamine (DA) release, which may lead to a reduction
in depressive-like symptoms
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potential antidepressant properties of a compound by
measuring of immobility time.15,16 In theory, immobility
time, or passive behavior, should reduce under antide-
pressant conditions.15,16 It has been hypothesized that
induction of DYN in the nucleus accumbens promotes
immobility during the forced swim test, in which case KOR
antagonists would oppose this mechanism, thus signifying
an antidepressant-like effect in animal models.16 The main
KOR antagonists that were modeled for antidepressant
properties include 50-guanidinonaltrindole, 50-acetamindi-
noethylnaltrindole, nor-binaltorphimine, and the 4-phenyl-
piperidine derivative JDtic.17-20 Although all produced
reductions in immobility time on the forced swim test,
they were never marketed because of concerns of slow
onset, toxic drug accumulation, poor oral bioavailability,
and/or cardiac toxicity.17-20
One such KOR antagonist, a combination product of
buprenorphine (BUP) and samidorphan (SAM), hereafter
referred to as BUP/SAM, has been granted Fast Track
designation by the US Food and Drug Administration.21
Samidorphan, also known as 3-carboxamido-4-hydroxy-
naltrexone, is a synthetic analog of naltrexone and is a
potent MOR antagonist. The original compound was
structurally modified to provide a 14-fold increase in
binding affinity to MORs and improve oral bioavailability,
given that oral administration of well-known MOR
antagonists, naloxone and naltrexone, is limited by poor
oral bioavailability.22,23 Buprenorphine is a partial MOR
agonist and KOR antagonist. Given its partial agonism at
MORs, it has been noted to be safer than conventional
opiates, as evidenced by its ‘‘ceiling effect’’ of respiratory
depression, subsequent lack of toxicity, and comparatively
mild withdrawal profile.24 When BUP and SAM are
administered concurrently, SAM, like naltrexone or
naloxone, acts to negate the agonistic effects that low-
dose BUP has at MORs. The antagonistic properties at
KORs from BUP remain, causing the combination product
to act primarily as a KOR antagonist.25 This contrivance
has been hypothesized as the proposed mechanism of
action for the new antidepressant combination product
BUP/SAM, as depicted in the Figure, part B. In summary,
BUP will enhance and stabilize endogenous opioid tone in
areas of deficiency and hyperactivity, respectively, where-
as SAM acts to negate abuse potential.
Buprenorphine has previously demonstrated antidepres-
sant-like properties in humans in a few studies.26-29 Of the
71 patients across these 4 studies,26-29 44 were male and
40 were opioid-addicted patients receiving maintenance
treatment. The studies26-29 were conducted anywhere
from 1 to 8 weeks, and BUP was initiated between 0.15
and 0.40 mg/d and titrated to 0.8 to 8.0 mg/d. All of the
studies26-29 used the sublingual formulation of BUP,
although 1 study27 also incorporated intranasal BUP.
Patients were assessed on a variety of scales, including
the Beck Depression Inventory, Six-item Short Depression
Scale, Hamilton Rating Scale for Depression (HAM-D),
Atypical Depression Diagnostic Scale, Profile of Mood
States, Global Assessment Scale, and Montgomery-
Asberg Depression Rating Scale (MADRS).26-29
The first study26 conducted observed that 12 of 19 opioid-
addicted, depressed patients met clinical criteria for
response at the end of the 1-month study. In addition,
maximal symptom reduction was observed rapidly at week
1 (n¼8), week 2 (n¼2), and week 3 (n¼2). The second
study27 noted significant improvement as early as week 1,
which was sustained through the end of the study at week
4. Of the 7 individuals who completed this, 4 met criteria for
remission, 2 for response, and 1 for no response. The third
study,28 which was the smallest and shortest study, included
6 patients in a 1-week, dose-titration study. At the end of
week 1, 5 of 6 patients met criteria for remission per change
in HAM-D scores, whereas 4 of 6 patients met criteria for
remission per change in Beck Depression Inventory scores.
Lastly, 15 patients were enrolled in an 8-week, dose-titration
study and were administered the MADRS weekly.29 There
were 8 patients who met criteria for response at the end of
the study (mean MADRS¼9.5); however, at week 16
telephone follow-up, which occurred after BUP discontinu-
ation at week 8, mean MADRS scores rose back to 17.8,
indicating the need for long-term treatment.
Despite the limitations of these studies, such as small
sample size, short duration, lack of information regarding
description of study design, variability in patient assess-
ment, and failure to report side effects or pertinent
statistics, BUP was able to demonstrate rapid onset of
antidepressant action. The combination of findings among
KOR antagonists in rodent models coupled with prelim-
inary findings of BUP as a rapid-acting antidepressant
serve as a strong pharmacologic rationale for the
development of BUP/SAM. As such, the objective of this
article is to analyze the results of BUP/SAM premarketing
clinical trials as adjunctive treatment for treatment-
resistant MDD.
Methods
A comprehensive PubMed/MEDLINE search was conduct-
ed through November 9, 2017, using the following search
terms: depression, samidorphan, buprenorphine, ALKS-
5461 (developmental code name). All English-language
clinical trials evaluating the combination of BUP/SAM in
the treatment of MDD on human participants were
included. Two researchers conducting this search yielded
2 unique results from search terms, of which both were
included. Three additional trials were included that were
obtained from Clinicaltrials.gov and resources included in
the present study.
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Results
A series of trials—Focused On Results with a Rethinking of
Depression, collectively referred to as the FORWARD trials—
evaluated BUP/SAM as adjunctive treatment for MDD, and a
summary of these results can be found in the Table.
FORWARD-1
The first FORWARD trial, referred to as FORWARD-1, was
a 2-part study25 that first evaluated the dose ratio of BUP
to SAM that was most effective at blocking opioid effects.
The first portion included 13 healthy, opioid-experienced,
nonaddicted, and non–treatment-seeking adults in a
single-center, double-blind, randomized, placebo-con-
trolled, crossover study. The participants were enrolled
into sequential cohorts where cohort 1 (n¼6) was
administered BUP/SAM dosages 8 mg/0 mg, 8 mg/1 mg,
and 8 mg/4 mg, and cohort 2 (n¼ 7) was administered
BUP/SAM 8 mg/0 mg, 8 mg/8 mg, and 8 mg/16 mg.
Within-cohort doses were administered in a blinded,
randomized fashion and were separated by 7- to 12-day
TABLE: Summary of premarketing clinical trials evaluating buprenorphine/samidorphan (BUP/SAM)
Design Assessment Results
FORWARD-125
 DB, R, PC, crossover study
 BUP 8 mg þ
SAM 0 mg, 1 mg, 4 mg (n ¼ 6)
SAM 0 mg, 8 mg, 16 mg (n ¼ 7)
 Objective blockade:
pupillometry
 Subjective blockade: VAS and
16-item opiate agonist scale
 Ratios ;8:1 and 1:1 achieved intermediate and
maximal levels, respectively, of blockade
 Most common ADEs were N/V, dizziness, fatigue
 In general, ADEs improved as ratio approached 1:1
 No clinically significant changes otherwise
 1-wk, DB, R, PC, parallel-group,
multiple-dose study
 BUP/SAM ratio 8:1 (n ¼ 14)
BUP/SAM ratio 1:1 (n ¼ 14)
HAM-D, MADRS  Significant improvement for dose ratio of 1:1
 Greater self-reported VAS scores in 8:1 group in
first 3 days for ‘‘high’’ and ‘‘sedation’’
 Most common ADEs were dizziness, N/V, sedation,
constipation, fatigue
 No clinically significant changes otherwise
FORWARD-230
 DB, R, PC, SPCD study
 BUP/SAM 2 mg/2 mg (n ¼ 47a)
BUP/SAM 8 mg/8 mg (n ¼ 41a)
HAM-D, MADRS, CGI-S, rate of
response, rate of remission
 Significant improvement for 2 mg/2 mg dose
 Significant rate of response/remission per MADRS
for 2 mg/2 mg dose
 Most common ADEs were N/V, headache, dizziness,
sedation
 No clinically significant changes otherwise
FORWARD-331,32,b
 DB, active-controlled, 4-wk placebo
run-in phase followed by 6-wk DB
efficacy phase
 BUP/SAM 2 mg/2 mg (n ¼ 164a)
MADRS  No significant improvement for 2 mg/2 mg dose
 Most common ADEs were nausea, headache,
constipation, dry mouth
 No serious ADEs occurred in active treatment
group
FORWARD-432,33,b
 DB, R, PC SPCD study
 BUP/SAM 0.5 mg/0.5 mg (n ¼ 115a)
BUP/SAM 2 mg/2 mg (n ¼ 116a)
MADRS  Significant improvement for 2 mg/2 mg dose;
significance first noted at week 3
 Most common ADEs were N/V, constipation,
dizziness, somnolence, headache
 No serious ADEs occurred in active treatment
group
FORWARD-534-36,b
 DB, R, PC SPCD study
 BUP/SAM 1 mg/1 mg (n ¼ 125a)
BUP/SAM 2 mg/2 mg (n ¼ 126a)
6-item and 10-item MADRS  Significant improvement for 2 mg/2 mg dose for
core and overall symptoms
 1 mg/1 mg dose displayed symptomatic
improvement but lacked significance
 Most common ADEs were nausea, dizziness, and
fatigue
ADE ¼ adverse drug event; CGI-S ¼ Clinical Global Impressions severity scale; DB ¼ double-blind; HAM-D ¼ Hamilton Rating Scale for Depression;
MADRS¼Montgomery-Asberg Depression Rating Scale; N/V¼ nausea/vomiting; PC¼ placebo-controlled; R¼ randomized; SPCD¼ sequential parallel
comparison design; VAS¼ visual analog scale.
aBoth groups combined.
bFull report of studies has not been published; thus, information contained in this table may be incomplete.
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washout periods. Patients were assessed for subjective
opioid effects via the visual analog scale (VAS) and the 16-
item opiate agonist scale. The VAS is an instrument
measuring level of agreement from ‘‘not at all’’ to
‘‘extremely’’ among subjective items, such as ‘‘bad
effects,’’ ‘‘good effects,’’ ‘‘high,’’ etc. The 16-item opiate
agonist scale required patients to rate the intensity of
subjective effects from ‘‘no effect’’ to ‘‘maximum effect.’’
Patients were also assessed for objective opioid effects via
pupillometry, which measures pupil diameter and can be
used to detect miosis. Lastly, a safety assessment was
conducted that included adverse drug event (ADE)
monitoring, vital signs, laboratory findings, physical
examinations, electrocardiogram, and pulse oximetry.25
Researchers found that objectively, maximal miosis
inhibition occurred at BUP/SAM doses of 8 mg/8 mg
and 8 mg/16 mg (P  .001) compared with 8 mg/0 mg.25 In
addition, VAS and 16-item opiate agonist scale scores
dose-dependently decreased with coadministration of
SAM. For safety and tolerability, the most common ADEs
in the BUP/SAM 8 mg/0 mg group were nausea (n¼ 7),
vomiting (n¼6), dizziness (n¼ 1), and fatigue (n¼ 1). In
general, the frequency of ADEs decreased as SAM dose
increased, and there were no clinically significant changes
on safety assessment measurements otherwise. Overall,
the authors concluded that BUP/SAM dose ratios of ;8:1
and 1:1 achieved intermediate and maximal levels of
blockade, respectively, and the medications were rela-
tively well tolerated at these dosage ratios.25
The second portion of the study25 was a randomized,
double-blind, placebo-controlled, parallel-group, multiple-
dose study designed to evaluate the safety, tolerability,
and efficacy of BUP/SAM dose ratios from the first part of
the study. The participants were 32 adults with MDD per
Diagnostic and Statistical Manual of Mental Disorders, 4th
edition, criteria who must have been in a current
depressive episode of at least 8 weeks with inadequate
response to stable dose of SSRI or SNRI antidepressant,
defined as less than 50% improvement in symptoms.
Diagnoses of bipolar disorder, psychosis, and personality
disorder were excluded; other exclusion criteria were risk
of suicide, or diagnosis of alcohol or illicit drug
dependence within the past 12 months of screening. The
participants were randomized to 1 of 3 treatment cohorts
for 7 days: (1) BUP/SAM 8:1 dose ratio (n¼ 14), (2) BUP/
SAM 1:1 dose ratio (n¼ 14), or (3) placebo (n¼4); all 3
treatment arms continued their current SSRI or SNRI
therapy. Cohort 1 received BUP/SAM 2 mg/0.25 mg for 3
days followed by 4 mg/0.5 mg for 4 days. Cohort 2
received BUP/SAM 4 mg/4 mg for 3 days followed by 8
mg/8 mg for 4 days. Patients were assessed daily on
safety measurements of ADE monitoring, vital signs,
laboratory findings, electrocardiogram, daily VAS, Addic-
tion Research Center Inventory-Morphine Benzedrine
Group (ARCI-MBG), and the Columbia Suicide Severity
Rating Scale (C-SSRS). Patients were also assessed on
efficacy measurements of HAM-D and MADRS at baseline
and on day 7.25
Researchers found that for efficacy, both BUP/SAM dose
ratios resulted in improvement on HAM-D and MADRS
from baseline to end of study.25 The HAM-D and MADRS
scores for BUP/SAM 8:1 at baseline were, respectively,
means (SDs) of 17.5 (2.0) and 23.3 (4.1), with changes of
5.0 (6.1) and8.5 (7.4), at the end of the study, although
neither reached statistical significance. The respective
HAM-D and MADRS scores for BUP/SAM 1:1 at baseline
were 19.4 (2.7) and 26.4 (4.4), with a statistically
significant change on HAM-D of 6.7 (3.4; P¼.032) and
a trend toward significance on MADRS 11.5 (6.5;
P¼.054). The most notable safety outcomes included
that the BUP/SAM 8:1 group reported higher VAS scores
compared with the BUP/SAM 1:1 group for feeling ‘‘high’’
and sedation. Lastly, the most notable tolerability
outcomes for BUP/SAM 8:1 and 1:1, respectively, included
the most common ADEs of dizziness (n¼8 and 4), nausea
(n¼4 and 3), vomiting (n¼4 and 2), constipation (n¼2
and 3), sedation (n¼ 3 and 1), and fatigue (n¼2 and 1).25
Of note, cohort 1 and cohort 2 each had 1 patient
discontinue treatment after the first study dose because
of vomiting. Lastly, upon abrupt discontinuation of study
drug, no opioid withdrawal was observed. Therefore,
coupled with the findings from the first portion of the
study, the authors concluded the most effective and
robust antidepressant effects were observed among
participants in the BUP/SAM 1:1 dose ratio group.25
FORWARD-2
As a follow-up to the 1-week FORWARD-1 pilot trial, the
FORWARD-2 trial was a multicenter, randomized, double-
blind, placebo-controlled study30 that used a 2-stage
sequential parallel comparison design (SPCD) to evaluate
the efficacy and safety of BUP/SAM. The SPCD is one that
can be used to enhance signal detection in studies with
relatively small sample sizes, something the authors
wanted to employ because of the high incidence of
placebo response in depression trials. The SPCD in
FORWARD-2 contained 2 stages, each consisting of 5
weeks, where participants received treatment for 4 weeks
and then underwent a 1-week washout period. During the
first stage, a larger portion of participants were random-
ized to placebo rather than active treatment. At the end
of the first stage, the participants who met criteria for
placebo nonresponse were then randomized to either the
active drug arm or placebo in the second stage. The
participants who were considered placebo responders
remained on placebo during stage 2.30
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Included were adults who met Diagnostic and Statistical
Manual of Mental Disorders, 4th edition, criteria for MDD,
were in a current episode of MDD for 4 months, had a
HAM-D score of 16 at screening, were receiving an SSRI
or SNRI at an adequate dose for at least 8 weeks, and had
an inadequate response to 1 or 2 courses of antidepres-
sants.30 There were many exclusion criteria, such as other
disease states (psychosis, substance or alcohol use),
improvement on HAM-D from screening to baseline visit,
any lifetime history of opioid dependence, adjuvant
therapy (including electroconvulsive therapy and psycho-
therapy), pregnancy, and suicide attempt within the past 2
years.30 Participants were administered HAM-D, MADRS,
and Clinical Global Impressions severity scale (CGI-S)
weekly to assess primary outcome of change in HAM-D
score from baseline to week 4, and secondary outcomes
of change in MADRS and CGI-S score from baseline to
week 4, rate of response, and rate of remission. Response
was defined as 50% reduction in HAM-D or MADRS
scores at week 4, and remission was defined as HAM-D
score 7 or MADRS score 10 at week 4. Safety and
tolerability were assessed via ADE monitoring, vital signs,
laboratory findings, VAS, Clinical Opiate Withdrawal Scale
(COWS), ARCI-MBG, and C-SSRS.30
From 31 sites within the United States, 142 participants
were randomized in stage 1 to either BUP/SAM 2 mg/2 mg
(n¼24), BUP/SAM 8 mg/8 mg (n¼ 19), or placebo
(n¼98).30 The participants who received active drug were
crossed over to placebo in stage 2, and from the placebo
group in stage one, 23 participants were placebo
responders and remained on placebo in stage 2. The
remaining 65 participants from the original placebo group
were randomized to BUP/SAM 2 mg/2 mg (n¼ 23), BUP/
SAM 8 mg/8 mg (n¼22), and placebo (n¼20).30
Efficacy assessment was significant for the BUP/SAM 2
mg/2 mg group, but nonsignificant, smaller changes
were observed in the BUP/SAM 8 mg/8 mg group
compared with placebo.30 For the BUP/SAM 2 mg/2 mg
group, differences from baseline to end of week 4 were
as follows: HAM-D (2.8, 95% confidence interval
[CI]¼5.1,0.6; P¼.014); MADRS (4.9, 95% CI¼8.2,
1.6; P¼.004); and CGI-S (0.5, 95% CI¼0.9, 0.1;
P¼.012). In addition, both active treatment arms
displayed a greater rate of response and remission
compared with placebo in both stages according to
HAM-D and MADRS, although only the BUP/SAM 2 mg/2
mg dose in stage 2 produced significantly more
responders (P¼.003) and remitters (P¼.003) than
placebo per MADRS scores.30
During stage 1, 7 participants discontinued BUP/SAM 2
mg/2 mg treatment (ADE, n¼4; lost to follow-up, n¼2;
withdrawal by patient, n¼ 1), and 5 discontinued BUP/
SAM 8 mg/8 mg (ADE, n¼ 5; lost to follow-up, n¼ 1).30
During stage 2, 5 participants withdrew from BUP/SAM 2
mg/2 mg because of ADE, and 4 withdrew from BUP/SAM
8 mg/8 mg because of an ADE. The specific ADEs leading
to discontinuation were not reported, although the most
common ADE leading to discontinuation was vomiting
(4.3%). Overall, the most common ADEs for BUP/SAM 2
mg/2 mg and BUP/SAM 8 mg/8 mg, respectively, were
nausea (34.0% and 34.2%), headache (8.5% and 31.7%),
dizziness (19.2% and 31.7%), vomiting (17.0% and 26.8%),
and sedation (14.9% and 14.6%). Of note, 3 serious ADEs
occurred including attempted suicide via drug overdose
(n¼ 1, placebo group), intraocular melanoma (n¼ 1), and
acute opioid withdrawal (n¼ 1), the last two both
occurring in the BUP/SAM 2 mg/2 mg group. The last
patient was reportedly taking prohibited opioid medica-
tion. There was no evidence of withdrawal per COWS
assessment, and VAS scores were generally neutral for all
groups. The ARCI-MBG produced inconsistent results of
higher scores in stage 1, but scores in stage 2 were similar
to that of placebo. The emergence of suicidal ideation per
C-SSRS assessment was reported to be low and similar
across all groups, although exact figures were not
reported. Otherwise, there were no clinically relevant
safety concerns. With this, the authors concluded that
although both dosage groups of BUP/SAM displayed
antidepressant activity, significant treatment effects were
observed in the BUP/SAM 2 mg/2 mg dosage group only.
In addition, although BUP/SAM was relatively well
tolerated, enhanced tolerability may be seen upon slower
titration.30
FORWARD-3
The first phase 3 efficacy study, the FORWARD-3 trial, was
conducted as a double-blind, active-control, 4-week,
placebo run-in phase followed by a 6-week double-blind
efficacy phase.31,32 The inclusion and exclusion criteria
were very similar to those of the FORWARD-2 trial.30-32
Participants were split into 2 groups: group 1 participants
had a HAM-D score of 20 at screening (n¼ 399) and
group 2 participants had a HAM-D score of 18 to 19 at
screening (n¼ 30).31,32 After the 4-week placebo run-in
phase for group 1, placebo responders (n¼ 77) were
continued on placebo while placebo nonresponders
(n¼297) were randomized to either BUP/SAM 2 mg/2
mg dose (n¼ 149) or placebo (n¼ 148) for the 6-week
efficacy phase.31,32 Participants in group 2 were random-
ized to BUP/SAM 2 mg/2 mg (n¼ 15) or placebo (n¼ 15)
for the duration of the 10-week study and were not
included in the efficacy assessment.31,32 Assessment of
efficacy was change in MADRS score from baseline
compared with placebo for group 1, and safety assess-
ment included ADE monitoring for groups 1 and 2.31,32
The change in MADRS scores from baseline to end of
study were not statistically different from that of
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placebo.32 In group 1, the most commonly reported ADEs
in the BUP/SAM 2 mg/2 mg group were nausea (n¼ 13),
headache (n¼6), constipation (n¼ 3), and dry mouth
(n¼ 3), which occurred more commonly across the board
compared with placebo. Similar ADE findings were noted
in group 2. Of note, 1 undisclosed serious adverse event
occurred in the placebo arm of group 1. In addition, there
were no signs of withdrawal or abuse potential. With this,
the authors32 concluded that efficacy results were not
statistically significant and were inconsistent with previous
findings. The authors concluded that this was likely due to
inadequate filtering of placebo response, because only
19% of participants were identified and filtered as such.
These findings prompted the employment of enhanced
placebo-response filtering in follow-up phase 3 studies.
FORWARD-4
The second phase 3 efficacy study, the FORWARD-4 trial,
was conducted as a randomized, double-blind, SPCD
study to enhance placebo response filtering.32,33 The
inclusion and exclusion criteria were very similar to those
for the FORWARD-2 and FORWARD-3 trials.30-33 Partici-
pants were randomized to either placebo (n¼251), or
active treatment of BUP/SAM 0.5 mg/0.5 mg (n¼ 59) or
BUP/SAM 2 mg/2 mg (n¼60) for stage 1 of SPCD.32,33 For
stage 2, the participants receiving active treatment
remained in those treatment arms.32,33 From the placebo
arm, the 83 placebo responders were continued on
placebo in stage 2 while the 168 placebo nonresponders
were randomized to BUP/SAM 0.5 mg/0.5 mg (n¼ 56),
BUP/SAM 2 mg/2 mg (n¼ 56), or placebo (n¼ 56).
Assessment of efficacy was change in MADRS score from
baseline compared with placebo, and safety assessment
included ADE monitoring for groups 1 and 2.
The changes in MADRS scores were statistically significant
for the BUP/SAM 2 mg/2 mg group (P¼.028), but not the
BUP/SAM 0.5 mg/0.5 mg group.32 In addition, statistical
significance was noted as early as week 3 for BUP/SAM 2
mg/2 mg group (P¼.02).32 The most commonly reported
ADEs for BUP/SAM 0.5 mg/0.5 mg and BUP/SAM 2 mg/2
mg, respectively, were nausea (n¼ 14 and 17), constipa-
tion (n¼4 and 10), dizziness (n¼4 and 8), somnolence
(n¼ 5 and 6), vomiting (n¼4 and 6), and headache (n¼ 7
and 5). Of note, 1 undisclosed serious adverse event
occurred in the placebo group. In addition, there were no
signs of withdrawal or abuse potential. With this, the
authors32 concluded that BUP/SAM 2 mg/2mg is an
efficacious and safe agent when used as adjunctive
treatment of MDD, a reinforcement of the FORWARD-2
trial findings. The authors32 were able to identify and filter
31% of participants as placebo responders, which is likely
why these results differed from that of FORWARD-3.
FORWARD-5
The FORWARD-5 trial is the largest phase 3 safety,
tolerability, and efficacy study of BUP/SAM as adjunctive
treatment of MDD.34-36 The trial was designed as a
randomized, double-blind, multicenter, placebo-con-
trolled, SPCD study.34-36 Inclusion and exclusion criteria
were very similar to those for the FORWARD-2 through
FORWARD-4 trials.31-36 Participants were randomly as-
signed in stage 1 to BUP/SAM 2 mg/2 mg (n¼63), BUP/
SAM 1 mg/1 mg (n¼63), or placebo (n¼280) for 5
weeks.34-36 At the end of stage 1, those who were
originally randomized to active drug remained on active
drug. In the placebo arm, placebo responders (n¼ 69)
remained on placebo while placebo nonresponders were
randomized to BUP/SAM 2 mg/2 mg (n¼ 63) and BUP/
SAM 1 mg/1 mg (n¼62).34-36 Buprenorphine/samidorphan
dosing was titrated starting at 0.5 mg/0.5 mg on days 1 to
3, 1 mg/1 mg on days 4 to 7, and 2 mg/2 mg on day 8, if
applicable.36 Efficacy was assessed based on average of
changes of 6-item MADRS (core symptoms of depression)
and 10-item MADRS (overall symptoms of depression)
scores, in addition to change in MADRS-10 score from
baseline to end of study. Safety was assessed on COWS
and the emergence of ADEs.34-36
Researchers announced that the BUP/SAM 2 mg/2 mg
dose displayed statistically significant reductions on 6-
item (1.5; P¼.018) and 10-item (1.7; P¼.026) MADRS
scores from week 3 to end of treatment.35,36 In addition,
the most commonly reported ADEs reported for BUP/
SAM 1 mg/1 mg and 2 mg/2 mg, respectively, were nausea
(n¼9 and 17), dizziness (n¼6 and 7), fatigue (n¼ 5 and
7), vomiting (n¼ 3 and 6), constipation (n¼9 and 5), and
headache (n¼4 and 5).35,36 Of note, 5 serious ADEs
occurred in the active drug group, although none were
considered study drug related.36 In addition, there were
no signs of withdrawal or abuse potential.36 With this,
authors concluded that the BUP/SAM 2 mg/2 mg dose
was efficacious and safe as adjunctive treatment in MDD.
Conclusion
Because of the high chronicity and increased risk of
mortality associated with MDD, there is a need for the
exploration of medications targeting novel treatment
pathways in addition to serotonin, norepinephrine, and
DA. Buprenorphine/samidorphan is a novel antidepressant
working via the opioid receptor pathway to ultimately
increase dopaminergic transmission in the mesolimbic
pathway.
Past trials of BUP in the treatment of MDD were favorable
in terms of antidepressant properties, albeit limited
because of risk of abuse. With the addition of SAM, a
MOR antagonist, this combination will theoretically
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negate the concern over addictive-like properties at the
MOR while maximizing potential antidepressant opioider-
gic activity at the KOR. Early trials of BUP/SAM identified
that the ideal ratio of BUP to SAM was 1:1 to block opioid
abuse liability, as measured by mu-associated properties
of euphoria, drug-liking, and pupillary miosis.
Similarly, previous studies of KOR antagonists have also
displayed prominent antidepressant properties; however,
these agents fell short of marketing potential because of
their decreased systemic availability and concerns for
accumulation and toxicity. In phase 3 clinical trials of BUP/
SAM, there was no evidence of withdrawal or abuse
among the study participants. In addition, BUP/SAM
performed well to reduce HAM-D, MADRS, and CGI-S
scores, specifically with that of the BUP/SAM 2 mg/2 mg
dose. The antidepressant properties were evident as early
as week 3, which could pose as a unique, fast-acting
property known to be atypical of traditional antidepres-
sants. In October 2016, positive results from the
FORWARD-5 trial were initially announced indicating that
steps will be taken to market BUP/SAM within the United
States as an adjunctive treatment option for patients with
MDD. The complete, official results from the FORWARD-3
through FORWARD-5 trials have not been published as of
November 2017, although the results remain anticipated.
Interpretation of the clinical trials investigating BUP/SAM
are largely limited by small sample size, short duration of
follow-up at less than 12 weeks, and lack of long-term
follow-up. Also, using VAS scales in opioid-naive de-
pressed participants is considered exploratory because
they are not validated in this population. In addition,
participants were not allowed to have more than 2 trials
of inadequate response to antidepressant therapy. There-
fore, although these participants are still considered
treatment resistant by definition, participants who have
failed multiple antidepressants across multiple classes
have not been captured in these analyses. In turn, this
compromises the translation of efficacy to real-life
practice. Most concerning is that patients with a history
of substance abuse or alcohol dependence were excluded
from the FORWARD trials; therefore, the safety and long-
term effects in this patient population remain unknown.
Also, full results of the FORWARD-3 through FORWARD-5
trials have yet to be published, limiting the degree of
clinical interpretation. Lastly, a comparison of BUP/SAM
to other agents used as adjunctive therapy in MDD, such
as antipsychotics, is lacking. With this, it is difficult to
assess the usefulness of BUP/SAM (1) for longer than 12
weeks of treatment, (2) in those resistant to more than 2
antidepressants, (3) in those with a history of opioid or
alcohol dependence, and (4) compared with other agents
used as adjunctive therapy for MDD.
Despite this, BUP/SAM has generated evidence to support
its role as adjunctive therapy in the treatment of MDD. By
combining a KOR antagonist with other first-line MDD
options, such as an SSRI, SNRI, mirtazapine, or bupropion,
there can be an increase in the neurobiologic coverage
across serotonergic, noradrenergic, dopaminergic, and
opioidergic pathways. Additional studies are still needed
to compare BUP/SAM to other agents used as adjunctive
treatment in MDD; in special populations, such as in
patients with co-occurring substance abuse; and as a
monotherapeutic antidepressant option. Overall, advance-
ment in the treatment of MDD with the novel medication
BUP/SAM has shown to be a progressive option in
expanding our antidepressant armamentarium. Buprenor-
phine/samidorphan may prove to be a vital treatment
option for individuals who have exhausted at least 2
classic antidepressant pharmacotherapy agents, and may
lead to the dawning of a new age for antidepressant drug
development.
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